Registry following patients with prostate cancer receiving lutetium vipivotide tetraxetan
Records how lutetium vipivotide tetraxetan is used in people with spread prostate cancer.
Plain-language title generated from the registry record
Registry title: PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- BaselBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07484269
- Record updated
- 30 October 2026
- Original description
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancerRead full original descriptionShow less
Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Inclusion: Age ≥ 18 years at index date; Diagnosis of mPC; PSMA positive; Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date; Exclusion criterion:; Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer).